Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dipyrone Antipyretic Use Reported By 38% Of San Diego Hispanics - Survey

This article was originally published in The Tan Sheet

Executive Summary

More than one-third of Hispanic patients surveyed in two San Diego community medical clinics reported using Hoechst AG's Neo-melubrina (dipyrone), an antipyretic drug banned by FDA but available over-the-counter in many European and Latin American countries, including Mexico.

You may also be interested in...



Supplement Health Fraud International Cooperation Urged At Hearing

Improved international collaboration could aid in the fight against dietary supplement health fraud, Sen. Ron Wyden (D-Ore.) suggested at a Senate Special Committee on Aging hearing Sept. 10.

Supplement Health Fraud International Cooperation Urged At Hearing

Improved international collaboration could aid in the fight against dietary supplement health fraud, Sen. Ron Wyden (D-Ore.) suggested at a Senate Special Committee on Aging hearing Sept. 10.

Supplement Health Fraud International Cooperation Urged At Hearing

Improved international collaboration could aid in the fight against dietary supplement health fraud, Sen. Ron Wyden (D-Ore.) suggested at a Senate Special Committee on Aging hearing Sept. 10.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093008

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel